FBXO45 and non-small cell lung carcinoma: To assess whether Fbxo45 contributes to Afatinib resistance in NSCLC cells, we exposed four cell lines with abrogating or non‐abrogating Fbxo45 to a low dose of Afatinib (1 μm) for observing the ability of cell colony formation.